Homeostasis under hypoxic conditions is maintained through a coordinated transcriptional response mediated by the hypoxia-inducible factor (HIF) pathway and requires coactivation by the CBP and p300 transcriptional coactivators. Through a target-based high-throughput screen, we identified chetomin as a disrupter of HIF binding to p300. At a molecular level, chetomin disrupts the structure of the CH1 domain of p300 and precludes its interaction with HIF, thereby attenuating hypoxia-inducible transcription. Systemic administration of chetomin inhibited hypoxia-inducible transcription within tumors and inhibited tumor growth. These results demonstrate a therapeutic window for pharmacological attenuation of HIF activity and further establish the feasibility of disrupting a signal transduction pathway by targeting the function of a transcriptional coactivator with a small molecule.
Introduction
downstream mediators of signal transduction, such as activated transcription factors or transcriptional complexes. Hypoxia is an almost universal hallmark of solid tumors Signal transduction pathways translate extracellular signals and environmental stimuli into changes in the gene expression pro- (Vaupel et al., 1998; Zhong et al., 1999) . Adaptation to hypoxia is critical for tumor survival and growth and is mediated in large file of cells. In cancer, many oncogenic changes deregulate signal transduction pathways (Darnell, 2002) . Additionally, sigpart by transcriptional activation of genes that facilitate shortterm adaptive mechanisms (e.g., increased vascular permeabilnal transduction pathways also play key roles in maintaining tumor cell homeostasis, for example, adaptation to hypoxia by ity, vasodilatation, glucose transport, switch to anaerobic metabolism), as well as long-term adaptive mechanisms (e.g., angiinduction of hypoxia-inducible factor (HIF) and expression of vascular endothelial growth factor (VEGF) (Huang and Bunn, ogenesis) (Harris, 2002; Huang and Bunn, 2003; Pugh and Ratcliffe, 2003; Semenza, 2002) . This coordinated homeostatic Pugh and Ratcliffe, 2003; Semenza, 2002) . Efforts to target key components of signal transduction pathways have reresponse is mediated in large part through the activation of the heterodimeric transcription factor hypoxia-inducible factor sulted in therapeutic successes, most often through inhibition of receptors or upstream signal mediators. For example, tras-1 (HIF-1). Tumor hypoxia and overexpression of HIF-1 have been associated with resistance to certain therapies, increased tuzumab, imatinib mesylate, and rituximab, exemplars of the modern paradigm of targeted therapies, all target cell surface risk of invasion and metastasis, and poor outcome in certain malignancies (Hockel and Vaupel, 2001 ). receptors. There are few examples of success in targeting A number of strategies to preferentially target hypoxic tumor cells have been devised. The first to achieve clinical utility has been the development of drugs that have heightened toxicity under hypoxic conditions, for example, tirapazamine, a hypoxiaactivated topoisomerase II inhibitor (von Pawel et al., 2000) . Experimental approaches include gene therapy constructs containing HREs that drive expression under hypoxic conditions and prodrug activation by obligate anaerobic microbes (Brown, 2002) . Additionally, recent reports have identified inhibition of the HIF pathway by antimicrotubule agents (Mabjeesh et al., 2003) , topoisomerase inhibitors (Rapisarda et al., 2002) , histone deacetylase inhibitors (Mie Lee et al., 2003) , and HSP90 inhibitors (Hur et al., 2002; Isaacs et al., 2002; Mabjeesh et al., 2002) , although the specificity of these effects and relevance vis-à -vis their antitumor activities in vivo is not clear.
We and others have previously shown that p300 and CBP are critical coactivators of the HIF-1 pathway (Arany et al., 1996; Carrero et al., 2000; Ema et al., 1999; Kung et al., 2000) . Disrupting the normal interaction of p300/CBP with HIF-1␣ by retroviral overexpression of a blocking polypeptide resulted in di- growth in xenograft models (Kung et al., 2000) . While these B: Time-resolved fluorescence HTS for inhibitors of HIF-p300 binding. Biotinylapproaches provide experimental support for the importance ated HIF-1␣ polypeptide (TADC) was immobilized on streptavidin plates. In of the HIF pathway in tumorigenesis, therapeutic delivery of the presence of compounds, the binding of bacterially produced moderate-sized blocking polypeptides is not readily feasible.
was probed with a europium (Eu)-conjugated anti-GST antibody. C: Structure of chetomin.
Although pharmacological manipulation of nuclear protein-protein interactions has proven difficult (Cochran, 2000) , there have been a limited number of recent successes (Berg et al., 2002; Lepourcelet et al., 2004) . Here, we describe a target-based Many of the mechanisms that regulate the HIF-1 pathway screen that identified a small molecule inhibitor of the interaction have been recently elucidated ( Figure 1A ). Under conditions of of HIF-1 with p300. We demonstrate that the small molecule normal oxygenation, the regulated ␣-subunit (HIF-1␣) is hydroxattenuates hypoxia-inducible transcription in cell culture, as well ylated on prolines 402 and 564 in oxygen-dependent reactions, as within tumor xenografts, and has antitumor efficacy in vivo. targeting HIF-1␣ to the von Hippel-Lindau (vHL) ubiquitination complex and ultimate degradation by the proteasome system Results (Huang et al., 1998; Ivan et al., 2001; Jaakkola et al., 2001; Kallio et al., 1999; Masson et al., 2001) . In this manner, HIF-1␣ High-throughput screen for disrupters abundance is maintained at nominal levels under normoxic conof HIF-1␣/p300 binding ditions. As oxygen becomes rate limiting, proline hydroxylation
We developed a high-throughput screen (HTS) to search for diminishes, and HIF-1␣ accumulates and heterodimerizes with small molecules capable of disrupting the interaction of HIF-1␣ the constitutively present ␤-subunit (HIF-1␤, aryl hydrocarbon with p300 ( Figure 1B) . A biotinylated, 41 amino acid polypeptide nuclear translocator) (Huang and Bunn, 2003; Pugh and Rat- corresponding to the minimal p300/CBP binding domain of HIFcliffe, 2003) . A third site of regulatory hydroxylation on aspara-1␣ (TADC; residues 786-826 [Kung et al., 2000] ) was synthesized gine 803 is also inhibited under hypoxic conditions, allowing and immobilized on streptavidin-coated multiwell plates. The for recruitment of the p300 and CREB binding protein (CBP) minimal HIF-1␣ binding domain of p300 (CH1; residues 302-transcriptional coactivators (Lando et al., 2002) . Binding of this 423 [Kung et al., 2000] ) was produced in bacteria as a fusion complex to the cognate hypoxia-response element (HRE) reto glutathione-S-transferase (GST-CH1). Binding of GST-CH1 sults in transactivation of genes containing such elements within to immobilized TADC, in the presence or absence of compromoter or enhancer elements (Semenza, 2002) . pounds, was probed by europium-conjugated anti-GST antiThe near universality of hypoxia in human tumors and cenbody and detected by time-resolved fluorescence. The optimized HTS assay had an average signal-to-noise ratio of greater trality of the HIF pathway in adapting to hypoxia suggests that inhibition of the HIF pathway may have therapeutic utility as an than 5:1 and a very robust assay quality parameter ZЈ factor value (Zhang et al., 1999) of 0.82. antitumor strategy. Inhibition of HIF function in tumors may attenuate angiogenesis and may contribute directly to tumor A natural and synthetic compound library of Ͼ600,000 substances was subjected to this HTS. Compounds with Ͼ50% cell death through metabolic derangement. While some experimental xenograft studies support targeting the HIF pathway as inhibitory activity were titrated to determine a dose-response relationship (7 point IC 50 ). Due to the high binding affinity of an antitumor strategy (Kondo et al., 2002; Kung et al., 2000) , other mouse genetic experiments have had conflicting results these polypeptides (Freedman et al., 2002 (Freedman et al., , 2003 , the hit rate was low. There were only 187 titrated hits (0.03% titrated hit (Carmeliet et al., 1998; Hopfl et al., 2002; Ryan et al., 1998 Ryan et al., , 2000 , thus necessitating caution as this strategy is translated rate), which were then subjected to secondary assays consisting of an in vitro interaction assay of full-length HIF-1␣ with GSTto clinical utility. Figure  S1 at http://www.cancercell.org/cgi/content/full/6/1/33/ DC1) corresponded with those published for chetomin (Fujimoto et al., 2004; McInnes et al., 1976) . The optical rotation [␣] D 23 was ϩ283.2Њ (c ϭ 0.101 in chloroform; data not shown), which was likewise consistent with the published data of chetomin (Fujimoto et al., 2004) , confirming the absolute stereochemistry as indicated ( Figure 1C ). The final purity of chetomin used for these studies was Ͼ98% by HPLC analysis.
Chetomin disrupts HIF-1␣ and HIF-2␣ binding to p300
The structural elements that are required for HIF-1␣ binding to p300 are largely identical in HIF-2␣ (Freedman et al., 2002) . We evaluated the ability of chetomin to disrupt binding of HIF-1␣ and HIF-2␣ to p300 in an in vitro interaction assay. Full-length in vitro-translated HIF-1␣ and HIF-2␣ bound efficiently to GST-CH1 ( Figure 2A ). Addition of chetomin disrupted binding of both HIF-1␣ and HIF-2␣ at similar concentrations.
In cell culture, the interaction of the TADC domain of HIF-1␣ with the CH1 domain of p300 was evaluated using a mammalian two-hybrid assay. Here, the interaction of CH1 (p300 aa 311-528) fused to the VP16 activation domain (VP16-CH1) and the TADC domain of HIF-1␣ (aa 776-826) fused to the Gal4 DNA binding domain (Gal4-TADC) was measured in Hep3B cells. The hypoxia-induced interaction between TADC and CH1 was attenuated in a dose-dependent manner by chetomin over a low nanomolar range ( Figure 2B ). Prior studies have demonstrated a binding to p300 (Ema et al., 1999; Gu et al., 2001 ). Covalent to GST-CH1 in the absence or presence of chetomin at the indicated conattack of Cys800 in TADC by chetomin was excluded as a centrations or to GST as a negative control.
possible mechanism of action, since chetomin was equally effi-B: Mammalian two-hybrid interaction assay. Hep3B cells were cotransfected with VP16-CH1 and the indicated Gal4-fusion of HIF-1␣ (G4-HIF), an cacious against a Cys800Val mutant of TADC ( Figure 2B ) that interacting mutant (G4-HIF-C800V), or a noninteracting mutant (G4-HIFhas been previously reported to bind CH1 with heightened affin-C800S). Relative two-hybrid interaction was determined under normoxic ity (Gu et al., 2001 ). There were significant differences in chetoor hypoxic conditions and in the absence or presence of the indicated min doses required to disrupt HIF-1␣/CH1 interaction in vitro concentrations of chetomin. Reporter activity is normalized to an internal transcriptional control (␤-galactosidase activity) and expressed as the aver- conditions. HIF-1␣ was immunoprecipitated (IP HIF-1␣) from normalized aliTo determine if chetomin disrupted the interaction of endogquots of nuclear extract, and HIF-1␣ and p300 were detected by immunoblot. Cellular abundance of p300 was determined by immunoblot of 50 enous HIF-1␣ with p300, endogenous HIF-1␣ was immunopreg of unfractionated nuclear extract (NE).
cipitated from cells, and coimmunoprecipitated p300 was detected by immunoblot. As expected, under normoxic conditions the abundance of HIF-1␣ is nominal ( Figure 2C ). Under hypoxic conditions, HIF-1␣ is readily detectable and exists in complex CH1 (see Figure 2A ) and a cell-based assay utilizing the hypoxiawith p300. While chetomin had no appreciable effect on abunresponsive erythropoietin (EPO) enhancer driving luciferase (see dance of HIF-1␣ or p300 under hypoxic conditions, the abun- Figure 4A ). From this HTS and secondary analyses, a single dance of p300 complexed with HIF-1␣ was significantly reduced submicromolar inhibitor or HIF-1␣/p300 interaction, chetomin upon treatment with chetomin ( Figure 2C ). Thus, chetomin dis-( Figure 1C ), was identified.
rupts p300/HIF-1␣ protein-protein interaction in vitro and within Chetomin, a dithiodiketopiperazine metabolite of the fungus cells. Chaetomium species, has been previously characterized as having antimicrobial activity (Brewer et al., 1972; Sekita et al., 1981) .
Chetomin disrupts CH1 structure/function Complete synthesis of chetomin has not been achieved, and
To test whether chetomin globally disrupts p300 function, we as such the compound used for subsequent studies was proevaluated the transcriptional activity of proteins binding to variduced by fermentation, followed by organic extraction, and purification by silica gel and reverse phase C18 chromatography.
ous domains of p300. The p300 binding domain of each protein are not protected from solvent exposure by the structural fold, exchangeable amide protons are rapidly replaced by deuterium ions, which do not have a NMR signal. Lower concentrations of chetomin delayed the onset of change and/or produced only a partial effect, and solvent alone (DMSO) had no effect on the NMR spectrum. Spectral changes observed with chetomin were similar to those caused by EDTA-mediated chelation of zinc ions coordinated by CH1 ( Figure 3B ), which is known to disrupt its structure (Freedman et al., 2002) . Mass spectroscopy demonstrated that chetomin does not covalently modify the CH1 domain or the HIF-1␣ peptide (data not shown). Taken together, these findings indicate that chetomin targets the CH1 domain of p300, disrupting its global fold and thereby preventing interaction with HIF-1␣, as well as other CH1-interacting proteins.
Chetomin attenuates hypoxia-inducible transcription
Having determined that chetomin disrupts binding of HIF to p300, we wanted to determine if chetomin attenuated hypoxiainducible transcription. Utilizing three hypoxia-responsive reporters in cell-based assays, chetomin was found to attenuate hypoxia-induced reporter activity at low nanomolar concentrations ( Figure 4A ). All luciferase values were normalized to the CMV-driven expression of ␤-galactosidase as an internal con- which indicates that chetomin was not directly perturbing the effect of chetomin on p300-mediated transcription is expressed as luciferase activity of luciferase. These effects were also not due to nonspeactivity normalized to an internal control for transcription. Where indicated, cells were exposed to hypoxia.
cific transcriptional repression or cytotoxicity, since standard-
Effect of chetomin on CH1 structure. One-dimensional proton NMR specization to an internal control would correct for decreased overall tra in the absence (CH1) or presence of solvent alone (DMSO), chetomin, cell numbers. Furthermore, there was no appreciable decrease or EDTA. Only the upfield alipathic region is shown.
in cell viability in HCT116, Hep3B, or human umbilical vein endothelial cells when grown in chetomin up to concentrations of 250 nM for 24 hr (data not shown).
To further verify effects on hypoxia-inducible transcription, was fused to the Gal4 DNA binding domain. p300-dependent real-time RT-PCR was used to quantify the abundance of a transcriptional activity was assayed as activity from a Gal4-panel of hypoxia-induced transcripts. Here too, chetomin reluciferase reporter. Chetomin had no significant effect on RAR, duced the abundance of multiple hypoxia-induced transcripts, SREBP2, or SRC-1 transcriptional activity ( Figure 3A) , demonalbeit with varying efficacy ( Figure 4B ). strating that chetomin did not globally inhibit p300 activity, as VEGF is a primary mediator of vascular permeability and these factors bind to the amino-terminal, KIX, and glutamineangiogenesis, and its production is induced by hypoxia (Figures rich domains, respectively. STAT2 transcriptional activity, how-4C and 4D). Cellular abundance ( Figure 4C ) as well as supernaever, was significantly attenuated by chetomin, in a manner tant levels of secreted VEGF ( Figure 4D ) protein were both attenparallel to HIF-1␣. Since STAT2 also binds to the CH1 domain uated by addition of chetomin in a dose-dependent manner. (Bhattacharya et al., 1996) , these data suggest that chetomin Taken together, these results demonstrate that chetomin attendisrupts CH1 function but not p300 function in entirety. These uates hypoxia-inducible gene expression in cell culture and is results also demonstrate that chetomin is not a nonspecific not a global inhibitor of transcription at the concentrations that transcriptional inhibitor.
were used in these studies. To more directly probe the effect of chetomin on CH1, we used NMR spectroscopy to determine the effect of chetomin Chetomin attenuates HIF pathway function in vivo on the structure of CH1 ( Figure 3B ). Addition of a 2-fold molar When chetomin was administered intravenously in mice, excess of chetomin to HIF-1␣ in complex with CH1 did not alter 2 mg/kg was the maximally tolerated single dose. Pharmacokithe 1D proton NMR spectrum (data not shown). In contrast, the netic analysis revealed variable peak plasma levels of 1375 Ϯ same amount of chetomin added to the CH1 domain alone 1020 nM that were achieved immediately after injection, with caused a loss of proton peak dispersion (i.e., the range over an elimination half-life of 4 hr. Peak xenograft tumor levels were which peaks are present) and broadening of spectral linewidths achieved 4 hr after a single intravenous dose, with peak tumor (i.e., the widths of the peaks that are present). These changes concentration of 300 nM (data not shown). indicate that CH1 becomes less structured in the presence of To determine if chetomin affected HIF-1 pathway in vivo, chetomin because spectral complexity is reduced when amino we first determined the effect of chetomin on serum EPO levels, acids become exposed to a uniform solute environment. This as a biomarker of physiological HIF-1 function (Semenza, 2002) . is further supported by the chetomin-induced disappearance Mice were treated either with three daily doses of chetomin at of amide proton peaks (i.e., centered around 8.35 ppm; data not shown) in a D 2 O-containing solvent. Here, when amino acids 2 mg/kg i.v. or with vehicle control. Serum was collected 6 hr after the final dose, and EPO was immunoprecipitated and then clearly visualized 48 hr after implantation ( Figure 6A) . Specificity of the reporter activity was validated by the fact that luminesquantified by immunoblot. Animals that were treated acutely with chetomin had a significant decrement in serum EPO levels cence was attenuated by concomitant expression of dnHIF polypeptide and superactivated by HIF-VP16, a constitutively ( Figure 6A ). Consistent with these acute effects, animals that were treated for 3 weeks with chetomin (see Figure 7A ) had active allele of HIF-1␣. The retroviral vector controls (pMMP and pBP) were comparable to otherwise unmodified reporter specific decreases in red blood cell counts ( Figure 6B ).
The effect of acute administration of chetomin on pathologicells ( Figure 6A ). Thus, the luminescent signal emanating from these reporter cells was a reflection of the transcriptional activity cal HIF-1 activity was evaluated in mice bearing established HCT116 xenograft tumors. Mice were again treated with either of the HIF-1 pathway within these tumors. To assess the in vivo effect of chetomin on hypoxia-inducible three daily doses of chetomin at 2 mg/kg i.v. or vehicle control. We evaluated the effect of chetomin on the expression of two transcription, we innoculated nude mice with hypoxia reporter cell line on the right flank (HepG2-EPO-Luc). As an internal HIF-1 target genes, glucose transporter 1 (Glut1) and VEGF, by immunohistochemistry and ELISA, respectively. Since oxygencontrol, a cell line with luciferase constitutively expressed from the CMV promoter was implanted on the left flank (HepG2-ation within tumors is highly heterogeneous, we examined Glut 1 immunoreactivity specifically in perinecrotic areas, where cells CMV-Luc). Mice were imaged 48 hr after implantation to establish baseline reporter activity and were then i.v. injected with are most hypoxic and there is peak hypoxia-driven gene expression (Damert et al., 1997) . VEGF levels were determined from either 2 mg/kg chetomin or vehicle control. After two doses, 24 hr after baseline imaging, mice were reimaged ( Figure 6B ). Total standardized tumor lysates. Chetomin was found to acutely attenuate both Glut1 expression ( Figure 5C ) and tumor VEGF flux of photons through a standardized region of interest drawn around each injection site was determined, and hypoxia-specific levels ( Figure 5D ), as biomarkers of HIF-1 activity within tumors.
To directly determine the effect of chetomin on the HIF-1 reporter activity was derived as the ratio of luminescence from EPO-Luc-containing cells relative to the constitutive internal pathway within tumors, we used in vivo bioluminescence imaging to quantify hypoxia-inducible transcription. We created a control (EPO-Luc/CMV-Luc). Hypoxia-specific reporter activity was marginally increased in vehicle-treated mice (ϩ11%, hypoxia reporter cell line in which luciferase was expressed under control of the EPO enhancer (HepG2-EPO-Luc). In cell ϩ13%) over the treatment period. In contrast, the hypoxia reporter activity in mice treated with chetomin was reduced by culture, this reporter cell line had Ͼ100-fold induction of reporter activity under hypoxic conditions when compared to normoxic approximately half (Ϫ40%, Ϫ52%). These results, together with the biomarker studies above, demonstrate that systemic adminconditions (data not shown). To validate the cell line for in vivo istration of chetomin attenuates both physiological and pathoassessment of hypoxia-induced transcription, aliquots of the logical HIF-mediated gene expression. reporter cell line were infected with retroviruses encoding dominant-negative (dnHIF) or dominant-positive (HIF-VP16) mediators of HIF-mediated transcription, as previously described
In vivo disruption of HIF/p300 interaction We adapted a previously described method for molecular im- (Kung et al., 2000) . When identical numbers of cells were implanted as xenografts in nude mice, bioluminescence was aging of protein-protein interactions (Ray et al., 2002 ) to evaluate the effect of chetomin on the interaction of HIF-1 with p300. As weeks), followed by a limited number of tail vein injections (1 week). In comparison to mice treated with vehicle control, with the cell culture mammalian two-hybrid assays described in Figure 2B , reporter cells were created by cotransfecting plas-2 mg/kg of chetomin given at the indicated frequency had significant antitumor activity ( Figure 7A ) without significant effects mids expressing Gal4-TADC and VP16-CH1. The activity of luciferase expressed from a Gal4-Luciferase vector was used on body weight over the treatment period ( Figure 7B ). Necropsy revealed coagulative necrosis at sites of tail vein injection (data as a quantitative measure of this protein-protein interaction (Ray et al., 2002) . Control cells were created by expressing the Gal4 not shown), and blood counts revealed anemia and leukocytosis ( Figure 5B ). We have not been able to determine the cause of DNA binding domain fused directly to VP16 (Gal4-VP16) to constitutively drive expression of Gal4-Luc. the local coagulative necrosis and leukocytosis but suspect that the latter may be a secondary effect of the former. There was We inoculated mice with two-hybrid reporter cells in the right flank and constitutive control cells in the left flank ( Figure  no other overt end-organ toxicity in chetomin-treated mice. When given at a lower dose of 1 mg/kg, the onset of local 6C). After 24 hr, mice were imaged to determine baseline reporter activity. Animals were then treated with either chetomin toxicity at sites of injection was significantly diminished. When chetomin was administered daily at 1 mg/kg i.v., there was (2 mg/kg) i.v. or vehicle control. After three daily doses, mice were reimaged ( Figure 6C ). In all cases, two-hybrid interaction likewise significant antitumor efficacy in mice xenografted with PC3 cells ( Figure 7C ). Histological examination of tumor secreporter luminescence was normalized to the control luminescence on the contralateral flank (i.e., to correct for cytotoxic or tions revealed significant necrosis in chetomin-treated tumors in comparison to minimal necrosis in vehicle-treated mice at nonspecific effects), and results are expressed relative to the baseline activity. With this molecular imaging approach, chetocomparable distances from the tumor surface ( Figure 7D ). Immunostaining for HIF-induced gene products (e.g., Glut1, VEGF) min was found to significantly disrupt the TADC/CH1 proteinprotein interaction within tumors in vivo ( Figure 6D ), as it did and vasculature revealed vast regional variability in chetomintreated tumors and were uninterpretable as to whether they in vitro (Figure 2A ) and in cell culture ( Figures 2B and 2C) .
were primary or late downstream treatment effects.
Effects of chetomin on tumor growth
We utilized xenograft tumor models to evaluate the effect of Discussion chetomin on tumor growth. HCT116 colon cancer cells were implanted subcutaneously and allowed to grow to approxiDisrupting the ability of tumors to adapt to hypoxia may be an attractive antitumor strategy given the universality of hypoxia mately 50 mm 3 prior to initiation of therapy. When given at 2 mg/kg, chetomin was found to cause local toxicity at sites of in solid tumors. Our prior studies demonstrated that attenuation of the HIF-1 pathway could be achieved through blockade of repeated intravenous injection, and this limited the number of doses that could be administered by tail vein injection. As such, the interaction of p300/CBP with HIF-1␣ through the overexpression of a blocking polypeptide in tumor cells (Kung et al., treatments were administered by injection through a central venous catheter for the effective lifespan of such catheters (2  2000) . Here, we describe our efforts to find a small molecule capable of blocking this nuclear protein-protein interaction. The by stromal elements (Fukumura et al., 1998) , and furthermore, attenuation of HIF may also have direct effects on endothelial primary candidate that emerged from a target-based HTS, chetomin, was found to indeed be able to block the interaction of cell viability or function as suggested by recent studies (Sowter et al., 2003; Yamakawa et al., 2003) . It is thus possible that, HIF-1␣ and HIF-2␣ with p300 by disrupting the HIF-interacting domain of p300. This resulted in attenuation of hypoxia-inducsince HIF-VP16 is expressed solely in the tumor cells, partial rescue results from the unimpeded effects of chetomin on host ible transcription in cell culture, as well as in vivo when systemically administered in mice.
elements. Although the precise function and requirement for the HIF pathway in the tumor and host compartments are active While the biomarker analyses (EPO/VEGF/Glut1 levels, in vivo molecular imaging) suggest that chetomin indeed hits areas of study, the current results with chetomin suggest a therapeutic window for inhibition of HIF function as a therapeutic its intended target, the HIF pathway and specifically HIF-p300 interaction, in vivo, the exact basis of the downstream antitumor target. We demonstrate that the HIF-1 pathway can be attenuated activity requires further investigation. Our attempts to rescue tumors from chetomin by overexpressing HIF-VP16 in tumor by blocking the function of an associated transcriptional coactivator. This approach does not confer absolute specificity of cells, as we have previously done (Kung et al., 2000) , resulted in only partial rescue of tumor growth (data not shown). One action, and our results suggest that other CH1-interacting transcriptional pathways are also blocked. Indeed, another possible possible explanation for this finding is that systemically administered inhibitors target both tumor and host elements (e.g., stroexplanation for partial rescue of tumor growth with HIF-VP16 (see above) is that chetomin may have off-target effects that mal cells, endothelial cells). The importance of the stroma in supporting tumor growth is underscored by the fact that a large contribute to antitumor efficacy. However, in our prior studies utilizing a polypeptide to block CH1, the in vivo antitumor effects fraction of VEGF within mouse tumors is actually produced were largely attributable to inhibition of the HIF pathway, since Modern drug discovery is increasingly focused on targeting pathognomonic changes in cancer cells. There are broad overexpressing HIF-VP16 largely rescued tumor growth (Kung et al., 2000) . Our results also demonstrate that chetomin is classes of targets, however, where selectivity may not result from absolute restriction in expression but rather from differenalso not totally nonspecific. That is, cellular transcription is not globally attenuated, as it is with actinomycin D, nor is the functial function in tumor cells in comparison to their normal counterparts. Recent clinical success with bortezomib, an inhibitor of tion of p300/CBP lost in entirety. Since p300 and CBP are critical coactivators of many transcriptional pathways that are proteosome function, is one such example. The HIF pathway ectopically activated in cancer, this strategy may have broader is another example, in that the pathway is present in all cells, utility in targeting other transcriptional pathways and transcripbut hypoxic tumors may have a heightened dependence upon tion factors. Attacking downstream mediators of transcription its function for survival and growth. While further development has the theoretical advantage of targeting common end efof chetomin as a therapeutic may be limited by its local toxicity, fectors in the case of pathways where mutations in multiple the results presented herein suggest that the HIF pathway can upstream components could all contribute to ectopic activation, be attenuated in vivo with a therapeutic window. Additional e.g., the WNT pathway (Morin et al., 1997) . Recent reports of target-based screens derived from our expanding knowledge peptidic (Lau et al., 2000) and small molecule inhibitors (Balasuof the molecular regulation of the HIF pathway or phenotypic bramanyam et al., 2003) of p300/CBP acetyltransferase activity cell-based screens utilizing hypoxia reporter cells (Rapisarda et suggest another method for attacking these coactivators.
al., 2002), will hopefully yield additional candidate compounds There are only a few examples where a signal transduction for development and evaluation as potential clinical therapathway has been disrupted by small molecule inhibition of a peutics. downstream protein-protein interaction (Berg et al., 2002 ; LeExperimental procedures pourcelet et al., 2004) . The interaction surface of p300/CBP with HIF-1␣ is extensive, totaling 3393 Å , and the a priori predicReagents, plasmids, and retroviruses tion would be that it would be difficult to find a small molecule Except where otherwise noted, all reagents were from Sigma. Mammalian capable of blocking this extended protein-protein interaction two-hybrid vectors pB42-CH1, pGal4-CAD, pGal4-CAD-C800V, and pGal4- (Freedman et al., 2002) . The mechanism of action in the case CAD-C800S were kind gifts of L. Eric Huang (National Cancer Institute) (Gu of chetomin appears to be disruption of the tertiary structure et al., 2001 ). pcDNA3-HA-HIF-2␣ was kindly provided by William G. Kaelin, Jr. (Dana-Farber Cancer Institute) . All other plasmids and retroviruses have of CH1. This result suggests that blockade of protein-protein been previously described (Bhattacharya et al., 1999; Kung et al., 2000) .
interactions may not require physical allosteric blockade of binding but rather may be accomplished through induction of struc- 
HIF-1/p300 HTS
formed with 2.5 g of total RNA added to buffer, random hexamers, dNTPs, RNase inhibitor, and reverse transcriptase (TaqMan; Applied Biosystems) GST-CH1 was expressed in BL21 pLysS cells (Promega), transformed with pGEX-2T-CH1 (aa 302-423) (Kung et al., 2000) , and grown in Luria-Bertani according to the manufacturer's instructions. Real-time PCR was then conducted using 5 l of template according to the manufacturer's instructions broth media supplemented with 0.1 mM ZnCl 2 . Expression was induced with 0.4 mM IPTG overnight at 25ЊC. The bacteria were lysed by sonication in (SYBR Green PCR; Applied Biosystems). Reactions were run and analyzed using the 5700 GeneAmp instrument and software (Applied Biosystems). lysis buffer (50 mM Tris 8.0, 150 mM NaCl, 100 M ZnCl 2 , 1 mM EDTA, 10 mM MgCl 2 , 1 mM dithiothreitol (DTT), 0.1% NP40, 50 g/ml RNAase A, 50 g/ml DNAase, 10 M pepstatin, 10 M leupeptin, and 1 mM Pefabloc
Immunoblot and ELISA analysis of VEGF [Roche] ). After centrifugation, GST-CH1 fusion protein was purified by GlutaHep3B cells were treated with compound or vehicle control (DMSO) for 8 hr thione-Sepharose 4B (Amersham) column chromatography according to the prior to addition of 125 M DFO to induce hypoxia response. After 18 hr, manufacturer's instructions. After elution with 50 mM glutathione, fractions cells were lysed in 100 mM Tris-Cl 6.8, 4% SDS, 20% glycerol, and protease with highest protein concentration were pooled and dialyzed overnight at inhibitor cocktail. After centrifugation, the protein concentration of the super-4ЊC in 2 liters of 50 mM Tris 8.0, 150 mM NaCl, 100 M ZnCl 2 , 1 mM DTT, natant was determined (BioRad), and 50 g of each lysate was resolved 0.1% NP40, 10% glycerol, and 0.1 mM Pefabloc. The GST-CH1 protein by SDS-PAGE on a 12% Tris-glycine gel. After transfer to nitrocellulose, was filtered and stored at Ϫ70ЊC.
immunodetection with anti-VEGF antibody (AB1442; Chemicon) was perMultiwell plates (Nunc) were coated with streptavidin 1 g/ml overnight formed using standard techniques. Tissue culture supernatant levels of VEGF at 4ЊC in PBS. The plates were washed with 50 mM Tris 8.0, 150 mM was determined using a VEGF immunoassay (R&D Systems) according to NaCl, and 0.05% Tween 20 (TBST). Synthetic N-terminal biotinylated HIFthe manufacturer's instructions. 1␣ peptide (aa 786-826) was bound in 50 mM Tris 8.0, 150 mM sodium chloride, and 5% bovine serum albumin (assay buffer) for 2 hr at 4ЊC. The
In vivo EPO and VEGF levels, Glut1 immunostain, plates were washed with TBST, and 111 pM GST-CH1 was added to the and blood counts plates in assay buffer with 0.1% Tween 20, 0.5 mM DTT, and 10 M ZnCl 2 NCr/Nude mice (Taconic) either with or without HCT116 xenografts were and in the presence or absence of compounds for 2 hr at 4ЊC. The assay treated for the indicated periods of time with chetomin or vehicle control plates were washed with TBST, and europium-labeled anti-GST antibody (10% DMSO, 4.5% dextrose). After humane euthanasia, blood was immediwas added in assay buffer with 10 M ZnCl 2 and incubated overnight at ately collected by intracardiac aspiration. For EPO levels, serum was isolated 4ЊC. The plates were washed with TBST, DELFIA enhancement solution using a serum separator tube (BDBioscience). Serum EPO was immunopre-(Wallac) was added, and fluorescence was read on a Victor I time-resolved cipitated from 200 l of serum using a polyclonal anti-mouse EPO antibody fluorescence detector (Wallac).
(Santa Cruz Biotechnology), followed by immunoblot with a monoclonal antibody (Pharmingen). Relative levels were determined by densitometry.
HIF-1␣/p300 immunoprecipitation
For blood counts, blood was collected in anticoagulant, and complete blood Hep3B cells were treated with 50 nM chetomin or DMSO for 2 hr prior to counts were performed by the clinical laboratory. For Glut1 and VEGF deteraddition of 125 M DFO. After 18 hr, cells were scraped into ice-cold PBS, mination, tumors were excised, and half of each tumor was fixed in buffered and nuclear extracts were prepared using the NE-PER kit (Pierce) according 10% formalin and then immunostained for Glut1 as previously described to the manufacturer's instructions. Standardized aliquots of 10 mg of nuclear (Kondo et al., 2002) . The other half of each tumor was flash frozen in liquid extract were incubated with 2 g each of OZ12 and OZ15 (Arany et al., 1996) nitrogen, pulverized to a powder with a mortar and pestle, and lysed in RIPA HIF-1␣-specific monocolonal antibodies for 2 hr at 4ЊC and immobilized on buffer (150 nM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, and 50 mM Tris Protein A/G Sepharose (Amersham) for 1 hr. Beads were extensively washed [pH 7.4]) containing protease inhibitors (Complete, Roche). Standardized with 50 mM Tris 8.0, 300 mM NaCl, 1% NP-40, 1 mM DTT, and protease aliquots of 0.1 mg of total protein were assayed using an ELISA specific for inhibitors (EDTA-free Complete, Roche). Samples were fractionated on SDShuman VEGF (R&D Systems) according to the manufacturer's instructions. PAGE, transferred to nitrocellulose, and immunoblotted with p300-specific (RW128) or HIF-1␣-specific (NB100; Novus) antibodies.
In vivo imaging and xenografts HepG2 cells (ATCC) were cotransfected with either EPO-luciferase (EPOIn vitro interaction and cell-based reporter assays Luc) or CMV-luciferase along with a neomycin phosphotransferase expresIn vitro pull-down, hypoxia reporter, and mammalian two-hybrid assays were sion vector. G418-resistent colonies were isolated and assayed for responperformed as previously described (Bhattacharya et al., 1999; Kung et al., siveness to hypoxia. A clone of HepG2 with stably integrated EPO-Luc was 2000). See the Supplemental Data at http://www.cancercell.org/cgi/content/ identified with Ͼ100-fold induction in cell culture. For validation, aliquots of full/6/1/33/DC1 for further details.
this clone were infected with pMMP, pMMP-dnHIF, pBP, or pBP-HIF-VP16 as described previously (Kung et al., 2000) . Xenografts were generated by NMR spectroscopy injecting 5 ϫ 10 6 of the indicated cells subcutaneously in NCr/Nude mice A complex of HIF-1␣/CH1 was prepared as previously described (Freedman (Taconic). Mice were anesthetized with a mixture of ketamine hydrochloride et al., 2002). CH1 alone was produced in a similar way but was purified (150 mg/kg), xylazine (12 mg/kg), and D-luciferin (50 mg/ml) (Xenogen, Alaby cation exchange (HiTrap SP HP; Amersham) followed by gel filtration meda, CA) and imaged utilizing the In Vivo Imaging System (IVIS; Xenogen) (Superdex75; Amersham). Samples were prepared by dissolving 125 M for a duration of 60-120 s. Mice were allowed to recover under isothermic unlabeled protein in 10 mM deuterated MES (pH 6.0), 90% D2O with or conditions after imaging. To quantify bioluminescence, identical standardwithout 100 mM NaCl, 0.1 mM ZnSO4, and 1 mM deuterated DTT. Oneized circular regions of interest (ROI) were positioned to encircle the areas dimensional 1 H NMR spectra were acquired on a Unity Inova 500 MHz of emission, and the integrated flux of photons through each ROI (photons/ spectrometer (Varian) at 25ЊC. Data were processed using the program s) was determined using the Living Images software package (Xenogen). PROSA, and the spectra were displayed using the program XEASY. ChetoFor in vivo two-hybrid interaction imaging, reporter cells were created min (25 mM) in 100% DMSO was added to protein samples in aqueous by transfecting HCT116 cells with expression vectors encoding Gal4-TADC, solution to final concentrations of 50 M, 100 M, and 250 M. In control VP16-CH1, and Gal4-Luc, as described in the Supplemental Data at http:// experiments, DMSO alone was added to protein samples using volumes www.cancercell.org/cgi/content/full/6/1/33/DC1. Control cells were cothat matched each of the chetomin additions (maximum 1% DMSO in each transfected with an expression vector encoding Gal4 DNA binding domain sample). EDTA (1 mM) was added to a protein sample containing 1% DMSO directly fused with the VP16 transactivation domain (Gal4-VP16) along with but not chetomin.
Gal4-Luc. Four hours after transfection with Lipofectamine 2000 (Invitrogen), 10 7 control cells were injected subcutaneously into the left flank, and 10 7 two-hybrid reporter cells were injected into the right flank. Animals were Real-time PCR Hep3B cells were treated with compound or vehicle control for 8 hr prior to imaged as described 24 hr after implantation and then divided into cohorts of mice which were treated with two doses of chetomin at 2 mg/kg or vehicle induction of hypoxia. Cells were maintained in hypoxia overnight, washed to remove debris, and total RNA was harvested using Trizol reagent (Invitrogen) control via tail vein injection (doses separated by 18 hr). Mice were reimaged 6 hr after the second dose (24 hr after first image). The flux of photons through according to the manufacturer's protocol. Reverse transcription was per-
